NeuroSense Therapeutics (NRSN) Stock Price, Quote, News & History | Benzinga

NeuroSense Therapeutics Ltd (NRSN) Stock Price, Quote, News & History

NRSNNASDAQ

Trade with Public

Trade with Public

$0.4204

-0.0185-4.22%

At close: Aug 28, 5:00 PM EST

$0.4227

0.00230.55%

After Hours: 6:06 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$0.44

Close

$0.42

Volume / Avg.

95.64K / 258.52K

Day Range

$0.42 - $0.45

52 Wk Range

0.25 - 1.98

Market Cap

$15.26M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

1.75%

Days to Cover

2.31

Recent Neurosense Therapeutics Ltd News

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include C3is, INLIF, and Polar Power. FIEE and KIDZ were among the top losers.

Avi Kapoor

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.

Avi Kapoor

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating.

Vandana Singh

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Avi Kapoor

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.67M

Investing Cash Flow (TTM)

-8.00K

Financing Cash Flow (TTM)

4.43M

Free Cash Flow (TTM)

-7.68M

Capital Expenditure (TTM)

-8.00K

Net Change in Cash (TTM)

-3.25M

Analyst Trends and Forecast

4

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$15.88M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-104.74%

Earnings Yield % (FWD)

-91.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.04

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$166.00K

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.44

Close

$0.42

Volume / Avg.

95.64K / 258.52K

Day Range

$0.42 - $0.45

52 Wk Range

0.25 - 1.98

Market Cap

$15.26M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

1.75%

Days to Cover

2.31

About

Sector

Health Care

Industry

Biotechnology

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy NeuroSense Therapeutics (NRSN) stock?

A

You can purchase shares of NeuroSense Therapeutics (NASDAQ:NRSN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are NeuroSense Therapeutics (NRSN) competitors?

A

Other companies in NeuroSense Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for NeuroSense Therapeutics (NRSN) stock?

A

NeuroSense Therapeutics has a consensus price target of $8.50.

Q

What is the current price for NeuroSense Therapeutics (NRSN)?

A

The stock price for NeuroSense Therapeutics (NASDAQ: NRSN) is $0.4227 last updated August 28, 2026 at 6:06 PM EDT.

Q

Does NeuroSense Therapeutics (NRSN) pay a dividend?

A

There are no upcoming dividends for NeuroSense Therapeutics.

Q

When is NeuroSense Therapeutics (NASDAQ:NRSN) reporting earnings?

A

NeuroSense Therapeutics does not have any upcoming earnings scheduled.

Q

Is NeuroSense Therapeutics (NRSN) going to split?

A

There is no upcoming split for NeuroSense Therapeutics.

Q

What sector and industry does NeuroSense Therapeutics (NRSN) operate in?

A

NeuroSense Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.